Advertisement
Advertisement
December 4, 2023
Boston Scientific Begins ROWAN Study of TheraSphere Y-90 Glass Microspheres With Immunotherapy to Treat HCC
_1701903977.jpg?auto=compress,format)
December 4, 2023—Boston Scientific has enrolled the first patient in the open-label, prospective, phase 2 ROWAN clinical trial, which is assessing the safety and effectiveness of using the company’s TheraSphere Y-90 glass microspheres in combination with immunotherapy to treat hepatocellular carcinoma (HCC).
The ROWAN study is composed of patients with HCC who are not candidates for resection, thermal ablation, or liver transplant at the time of study entry.
The single-arm global study will enroll 100 patients across 50 sites during the next 2 years. Patients will receive TheraSphere administered before initiation of durvalumab with tremelimumab.
According to the company, evidence suggests that tumors thrive by inhibiting the body’s natural immune response to cancerous cells. TheraSphere can cause tumor cell death, which can release new antigens that can help prime the immune system. The addition of immunotherapy may further enhance this immune response, allowing the immune system to respond more strongly to the cancer cells and limit tumor growth and recurrence.
The principal investigators of ROWAN are Beau Toskich, MD, of the Mayo Clinic in Jacksonville, Florida, and Aiwu Ruth He, MD, of MedStar Georgetown University Hospital in Washington, DC.
Advertisement
Advertisement
